Hancock Jaffe Laboratories will fund a pivotal trial of its VenoValve device to treat lower limb chronic deep venous insufficiency with $41.4m raised in a new public stock offering completed on 11 February.
Hancock Jaffe Sells $41.4M In Stock To Fund Venous Therapies
The new public offering will fund the US pivotal trial of the company’s VenoValve device to treat chronic deep venous insufficiency in the legs.
